Home › Funds › DAVENPORT & Co LLC › VRTX

DAVENPORT & Co LLC position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

DAVENPORT & Co LLC reported holding 202,800 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$106.2M, representing 0.67% of its reported portfolio and ranking #43 among its reported holdings. DAVENPORT & Co LLC has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)202.80K sh
Reported value held$106.23M
Portfolio Weight0.67%
First reportedQ3 2023
Last changeReduce
Updated2026-10-14

Last updated: 2026-10-14 · Source: SEC EDGAR Form 13F-HR

How DAVENPORT & Co LLC's VRTX position evolved

DAVENPORT & Co LLC first disclosed a stake in VRTX in Q3 2023 at 115,469 shares (US$40.3M). The position peaked in Q1 2025 at 225,310 shares, worth US$109.6M. Across 13 filings, DAVENPORT & Co LLC increased the stake 3 time(s), trimmed it 7 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 202,800 shares valued at US$106.2M — a reduction of -4,308 shares quarter over quarter.. Notable position changes include a 90% increase in Q4 2023 (shares rose 2% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 115.47K $40.26M New
Q4 2023 219.24K $89.25M Add
Q1 2024 218.79K $91.33M Hold
Q2 2024 221.53K $103.87M Add
Q3 2024 219.71K $102.07M Reduce
Q4 2024 218.07K $87.64M Reduce
Q1 2025 225.31K $109.63M Add
Q2 2025 226.18K $100.49M Hold
Q3 2025 217.28K $85.29M Reduce
Q4 2025 211.58K $95.94M Reduce
Q1 2026 210.15K $93.66M Reduce
Q2 2026 207.11K $103.03M Reduce
Q3 2026 202.80K $106.23M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 33 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$12.97B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has DAVENPORT & Co LLC held VRTX?

DAVENPORT & Co LLC has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is DAVENPORT & Co LLC's current position in VRTX?

As of Q3 2026, DAVENPORT & Co LLC holds 202.80K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $106.23M, representing 0.67% of its reported portfolio and ranking #43.

Has DAVENPORT & Co LLC been buying or selling VRTX?

In the latest 13F filing (Q3 2026), DAVENPORT & Co LLC reduced its position in VRTX. The position peaked in Q1 2025 at 225.31K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.